Maintenance Therapy in AML

por Reville, Patrick K., Kadia, Tapan M.
Publicado 2021

Maintenance therapy in acute myeloid leukemia: advances and controversies

por Senapati, Jayastu, Kadia, Tapan M., Ravandi, Farhad
Publicado 2023

Successful treatment of cutaneous adult T-cell leukemia/lymphoma with imiquimod

por Messer, Alison, Brown, Ashley E., Pacha, Omar, Boddu, Prajwal, Geppner, Alexis, Kadia, Tapan M., Huen, Auris O.
Publicado 2019

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies

por Birdwell, Christine, Fiskus, Warren, Kadia, Tapan M., DiNardo, Courtney D., Mill, Christopher P., Bhalla, Kapil N.
Publicado 2021

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

por Daver, Naval G., Maiti, Abhishek, Kadia, Tapan M., Vyas, Paresh, Majeti, Ravindra, Wei, Andrew H., Garcia-Manero, Guillermo, Craddock, Charles, Sallman, David A., Kantarjian, Hagop M.
Publicado 2022

Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia

por McCall, David, Roth, Michael, Mahadeo, Kris M., Toepfer, Laurie, Nunez, Cesar, Short, Nicholas J., Daver, Naval, Kadia, Tapan M., DiNardo, Courtney, Yi, Joanna S., Cuglievan, Branko
Publicado 2021

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)

por Ong, F., Kadia, T. M., Short, N. J., Yilmaz, M., Alvarado, Y., Pierce, S., Garcia-Manero, G., DiNardo, C., Borthakur, G., Konopleva, M., Daver, N., Kantarjian, H., Ravandi, F.
Publicado 2022

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

por Venugopal, Sangeetha, Borthakur, Gautam, Daver, Naval, DiNardo, Courtney D., Pemmaraju, Naveen, Short, Nicholas J., Abbas, Hussein A., Garcia-Manero, Guillermo, Konopleva, Marina, Ravandi, Farhad, Kadia, Tapan M.
Publicado 2022

Hematologic malignancies and Li–Fraumeni syndrome

por Swaminathan, Mahesh, Bannon, Sarah A., Routbort, Mark, Naqvi, Kiran, Kadia, Tapan M., Takahashi, Koichi, Alvarado, Yesid, Ravandi-Kashani, Farhad, Patel, Keyur P., Champlin, Richard, Kantarjian, Hagop, Strong, Louise, DiNardo, Courtney D.
Publicado 2019

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

por Fiskus, Warren, Manshouri, Taghi, Birdwell, Christine, Mill, Christopher P., Masarova, Lucia, Bose, Prithviraj, Kadia, Tapan M., Daver, Naval, DiNardo, Courtney D., Borthakur, Gautam, Khoury, Joseph D., Verstovsek, Srdan, Bhalla, Kapil N.
Publicado 2022

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL

por Jain, Nitin, Balakrishnan, Kumudha, Ferrajoli, Alessandra, O’Brien, Susan M., Burger, Jan A., Kadia, Tapan M., Cortes, Jorge E., Ayres, Mary L., Tambaro, Francesco Paolo, Keating, Michael J., Gandhi, Varsha, Wierda, William G.
Publicado 2016

Blast Phase Chronic Myelomonocytic Leukemia: Mayo-MDACC Collaborative study of 171 cases

por Patnaik, Mrinal M., Pierola, Ana A., Vallapureddy, Rangit, Yalniz, Fevzi F., Kadia, Tapan M., Jabbour, Elias J., Lasho, Terra, Hanson, Curtis A., Ketterling, Rhett P., Kantarjian, Hagop M., Tefferi, Ayalew, Garcia-Manero, Guillermo
Publicado 2018

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

por Alotaibi, Ahmad S., Yilmaz, Musa, Loghavi, Sanam, DiNardo, Courtney, Borthakur, Gautam, Kadia, Tapan M., Thakral, Beenu, Pemmaraju, Naveen, Issa, Ghayas C., Konopleva, Marina, Short, Nicholas J., Patel, Keyur, Tang, Guilin, Ravandi, Farhad, Daver, Naval
Publicado 2020

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

por Abbas, Hussein A., Sun, Hanxiao, Pierce, Sherry, Kanagal-Shamanna, Rashmi, Li, Ziyi, Yilmaz, Musa, Borthakur, Gautam, DiPippo, Adam J., Jabbour, Elias, Konopleva, Marina, Short, Nicholas J., DiNardo, Courtney, Daver, Naval, Ravandi, Farhad, Kadia, Tapan M.
Publicado 2022

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

por Mill, Christopher P., Fiskus, Warren, Das, Kaberi, Davis, John A., Birdwell, Christine E., Kadia, Tapan M., DiNardo, Courtney D., Daver, Naval, Takahashi, Koichi, Sasaki, Koji, McGeehan, Gerard M., Ruan, Xinjia, Su, Xiaoping, Loghavi, Sanam, Kantarjian, Hagop, Bhalla, Kapil N.
Publicado 2023

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

por Reville, Patrick K., Kantarjian, Hagop M., Ravandi, Farhad, Jabbour, Elias, DiNardo, Courtney D., Daver, Naval, Pemmaraju, Naveen, Ohanian, Maro, Alvarado, Yesid, Xiao, Lianchun, Alatrash, Gheath, Loghavi, Sanam, Rausch, Caitlin R., Borthakur, Gautam, Konopleva, Marina, Cortes, Jorge, Kadia, Tapan M.
Publicado 2021

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

por Fiskus, Warren, Daver, Naval, Boettcher, Steffen, Mill, Christopher P., Sasaki, Koji, Birdwell, Christine E., Davis, John A., Das, Kaberi, Takahashi, Koichi, Kadia, Tapan M., DiNardo, Courtney D., Burrows, Francis, Loghavi, Sanam, Khoury, Joseph D., Ebert, Benjamin L., Bhalla, Kapil N.
Publicado 2022

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies

por Thompson, Philip A., Peterson, Christine B., Strati, Paolo, Jorgensen, Jeff, Keating, Michael J., O’Brien, Susan M., Ferrajoli, Alessandra, Burger, Jan A., Estrov, Zeev, Jain, Nitin, Kadia, Tapan M., Borthakur, Gautam, DiNardo, Courtney D., Daver, Naval, Jabbour, Elias, Wierda, William G.
Publicado 2018

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

por Samra, Bachar, Richard-Carpentier, Guillaume, Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, DiNardo, Courtney D., Issa, Ghayas C., Bose, Prithviraj, Konopleva, Marina Y., Yilmaz, Musa, Ohanian, Maro, Borthakur, Gautam, Garcia-Manero, Guillermo, Pierce, Sherry, Cortes, Jorge E., Kantarjian, Hagop, Short, Nicholas J.
Publicado 2020

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

por Fiskus, Warren, Boettcher, Steffen, Daver, Naval, Mill, Christopher P., Sasaki, Koji, Birdwell, Christine E., Davis, John A., Takahashi, Koichi, Kadia, Tapan M., DiNardo, Courtney D., Jin, Qi, Qi, Yuan, Su, Xiaoping, McGeehan, Gerard M., Khoury, Joseph D., Ebert, Benjamin L., Bhalla, Kapil N.
Publicado 2022